Prognostic value of interleukin-1 receptor antagonist gene polymorphism and cytomegalovirus seroprevalence in patients with coronary artery disease

Table 3 Distribution of factors and relation to cardiovascular events during follow-up and partly and fully adjusted hazard ratios for cardiovascular events associated with Interleukin-1 receptor antagonist gene polymorphisms (IL-1RA) and serostatus of CMV

Factor	CVD-events during follow-up, row % (^ap-value)	^bPartly-adjusted hazard ratio (95% confidence interval)	^cFully-adjusted hazard ratio (95% confidence interval)
IL-1 RA
- other^d	20.4%	1^reference	1^reference
- Il-1RN*2	16.3% (0.73)	1.1 (0.80–1.66)	1.03 (0.60–1.76)
CMV-serostatus
- negative	20.7%	1^reference	1^reference
- positive		0.91 (0.55–1.52)	1.00 (0.59–1.72)
- positive, titre < median	16.7%	0.74 (0.38–1.43)	0.78 (0.40–1.54)
- positive titre ≥ median	22.1% (0.54)	1.12 (0.61–2.05)	1.32 (0.69–2.52)
IL-1 RA and CMV serostatus
- IL-other^d and CMV-negative	21.9%	1^reference	1^reference
- IL-other^d and CMV-positive	19.1%	0.86 (0.50–1.45)	0.94 (0.54–1.64)
- Il-1RN*2 and CMV-negative	12.5%	0.56 (0.13–2.36)	0.37 (0.08 – 1.67)
- Il-1RN*2 and CMV-positive	21.4% (0.83)	0.96 (0.32–3.43)	0.95 (0.27 – 3.38)

^a = according to log-rank test
^b = adjusted for age and gender
^c = adjusted for age, gender, body mass index, school education, cigarette smoking, alcohol consumption, history of myocardial infarction, history of hypertension, history of diabetes, statin intake, intake of aspirin, intake of diuretics
^d = all other alleles

ISSN: 1471-2261